Skip to main content

Table 1 (abstract O38). See text for description

From: 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Late-Breaking Abstracts

  Intermediate/poor risk
N+I S N+I
PD-L1 <1%
S
PD-L1 <1%
N+I
PD-L1 ≥1%
S
PD-L1 ≥1%
N=425 N=422 N=284 (74%)a N=278 (71%)a N=100 (26%)a N=114 (29%)a
ORR per IRRC, n (%) [95% CI] 177 (42)
[37-47]
112 (27)
[22-31]
106 (37)
[32-43]
79 (28)
[23-34]
58 (58)
[48-68]
25 (22)
[15-31]
  P<0.0001 Odds ratio (95% CI)=1.50 (1.04-2.17)b Odds ratio (95% CI)=4.92 (2.61-9.34)b
Median PFS per IRRC, months (95% CI) 11.6 (8.7-15.5) 8.4 (7.0-10.8) 11.0 (8.1-14.9) 10.4 (7.5-13.8) 22.8
(9.4-NR)
5.9
(4.4-7.1)
HR (CI) 0.82 (99.1% CI, 0.64-1.05) 1.00 (95% CI, 0.80-1.26) 0.46 (95% CI, 0.31-0.67)
  P=0.0331 P=0.9672b P<0.0001b
Median OS, months (95% CI) NR
(28.2-NE)
26.0
(22.1-NE)
NE (28.2-NE) NE (24.0-NE) NE 19.6 (14.8-NE)
HR (CI) 0.63 (99.8% CI, 0.44-0.89) 0.73 (95% CI, 0.56-0.96) 0.45 (95% CI, 0.29-0.71)
  P<0.0001 P=0.0249b P=0.0006b
  1. aPercentage based on number of PD-L1 evaluable patients. bExploratory unstratified analysis. NE, not estimable